Baxter Bros Inc. Sells 1,997 Shares of Bristol-Myers Squibb Company (BMY)
Baxter Bros Inc. trimmed its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 10.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,830 shares of the biopharmaceutical company’s stock after selling 1,997 shares during the quarter. Baxter Bros Inc.’s holdings in Bristol-Myers Squibb were worth $938,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Welch Investments LLC boosted its stake in shares of Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 79 shares in the last quarter. Blue Chip Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares in the last quarter. American National Bank boosted its stake in shares of Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares in the last quarter. Finally, V Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth about $126,000. 68.84% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://theolympiareport.com/2017/10/18/baxter-bros-inc-sells-1997-shares-of-bristol-myers-squibb-company-bmy.html.
Several equities research analysts have recently issued reports on the stock. Credit Suisse Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Wednesday, August 16th. BMO Capital Markets reissued an “underperform” rating and set a $47.00 target price (down from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. Leerink Swann lowered their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research note on Friday, July 28th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, Cowen and Company reissued a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $63.21.
Bristol-Myers Squibb Company (BMY) opened at 64.18 on Wednesday. The company’s 50 day moving average is $62.78 and its 200 day moving average is $56.98. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The firm has a market cap of $105.25 billion, a P/E ratio of 23.44 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.69 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.43%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.